SAREPTA THERAPEUTICS, INC. Revenue from Contract with Customer, Excluding Assessed Tax
SAREPTA THERAPEUTICS, INC. (SRPT) reported Revenue from Contract with Customer, Excluding Assessed Tax of $328.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $328.69M, a 35.94% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $330.51M, a 45.95% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $369.61M, a 42.08% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $370.04M, a 13.90% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.86B, a 4.27% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.79B, a 56.17% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.14B, a 35.69% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $843.77M, a 37.78% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $328.69M 10-Q · filed 2026-08-05 | $659.20M 10-Q · filed 2026-08-05 | $1.03B derived: sum of 3 quarters · filed 2026-08-05 | $1.40B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $330.51M 10-Q · filed 2026-05-06 | $700.12M derived: sum of 2 quarters · filed 2026-05-06 | $1.07B derived: sum of 3 quarters · filed 2026-05-06 | $1.58B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $369.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $739.65M derived: sum of 2 quarters · filed 2026-03-02 | $1.25B derived: sum of 3 quarters · filed 2026-08-05 | $1.86B 10-K · filed 2026-03-02 |
| 2025-09-30 | $370.04M 10-Q · filed 2025-11-06 | $883.17M derived: sum of 2 quarters · filed 2026-08-05 | $1.49B 10-Q · filed 2025-11-06 | $2.13B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $513.12M 10-Q · filed 2026-08-05 | $1.12B 10-Q · filed 2026-08-05 | $1.76B derived: sum of 3 quarters · filed 2026-08-05 | $2.19B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $611.52M 10-Q · filed 2026-05-06 | $1.25B derived: sum of 2 quarters · filed 2026-05-06 | $1.68B derived: sum of 3 quarters · filed 2026-05-06 | $2.04B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $638.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.07B derived: sum of 2 quarters · filed 2026-03-02 | $1.43B derived: sum of 3 quarters · filed 2026-03-02 | $1.79B 10-K · filed 2026-03-02 |
| 2024-09-30 | $429.77M 10-Q · filed 2025-11-06 | $790.32M derived: sum of 2 quarters · filed 2025-11-06 | $1.15B 10-Q · filed 2025-11-06 | $1.51B derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $360.55M 10-Q · filed 2025-08-06 | $720.03M 10-Q · filed 2025-08-06 | $1.09B derived: sum of 3 quarters · filed 2026-03-02 | $1.39B derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $359.48M 10-Q · filed 2025-05-06 | $724.55M derived: sum of 2 quarters · filed 2026-03-02 | $1.03B derived: sum of 3 quarters · filed 2026-03-02 | $1.27B derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $365.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $674.39M derived: sum of 2 quarters · filed 2026-03-02 | $913.38M derived: sum of 3 quarters · filed 2026-03-02 | $1.14B 10-K · filed 2026-03-02 |
| 2023-09-30 | $309.32M 10-Q · filed 2024-11-06 | $548.31M derived: sum of 2 quarters · filed 2024-11-06 | $779.80M 10-Q · filed 2024-11-06 | $1.02B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $238.99M 10-Q · filed 2024-08-07 | $470.48M 10-Q · filed 2024-08-07 | $706.42M derived: sum of 3 quarters · filed 2025-02-28 | $914.19M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $231.50M 10-Q · filed 2024-05-01 | $467.43M derived: sum of 2 quarters · filed 2025-02-28 | $675.20M derived: sum of 3 quarters · filed 2025-02-28 | $886.44M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $235.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $443.71M derived: sum of 2 quarters · filed 2025-02-28 | $654.94M derived: sum of 3 quarters · filed 2025-02-28 | $843.77M 10-K · filed 2025-02-28 |
| 2022-09-30 | $207.77M 10-Q · filed 2023-11-01 | $419.01M derived: sum of 2 quarters · filed 2023-11-01 | $607.84M 10-Q · filed 2023-11-01 | $786.56M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $211.24M 10-Q · filed 2023-08-02 | $400.06M 10-Q · filed 2023-08-02 | $578.79M derived: sum of 3 quarters · filed 2024-02-28 | $745.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $188.82M 10-Q · filed 2023-05-02 | $367.55M derived: sum of 2 quarters · filed 2024-02-28 | $534.46M derived: sum of 3 quarters · filed 2024-02-28 | $676.30M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $178.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $345.64M derived: sum of 2 quarters · filed 2024-02-28 | $487.48M derived: sum of 3 quarters · filed 2024-02-28 | $612.40M 10-K · filed 2024-02-28 |
| 2021-09-30 | $166.91M 10-Q · filed 2022-11-02 | $308.75M derived: sum of 2 quarters · filed 2022-11-02 | $433.68M 10-Q · filed 2022-11-02 | $556.32M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $141.84M 10-Q · filed 2022-08-02 | $266.76M 10-Q · filed 2022-08-02 | $389.41M derived: sum of 3 quarters · filed 2022-08-02 | $510.84M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $124.93M 10-Q · filed 2022-05-04 | $247.57M derived: sum of 2 quarters · filed 2022-05-04 | $369.00M derived: sum of 3 quarters · filed 2022-05-04 | $480.34M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $122.64M 10-K · filed 2021-03-01 | $244.07M derived: sum of 2 quarters · filed 2021-11-03 | $355.42M derived: sum of 3 quarters · filed 2021-11-03 | $455.87M 10-K · filed 2023-02-28 |
| 2020-09-30 | $121.43M 10-Q · filed 2021-11-03 | $232.77M derived: sum of 2 quarters · filed 2021-11-03 | $333.22M 10-Q · filed 2021-11-03 | $433.33M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $111.34M 10-Q · filed 2021-08-04 | $211.79M 10-Q · filed 2021-08-04 | $311.90M derived: sum of 3 quarters · filed 2021-08-04 | $410.95M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $100.45M 10-Q · filed 2021-05-05 | $200.56M derived: sum of 2 quarters · filed 2021-05-05 | $299.60M derived: sum of 3 quarters · filed 2021-05-05 | $394.27M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $100.11M 10-K · filed 2021-03-01 | $199.15M derived: sum of 2 quarters · filed 2021-03-01 | $293.82M derived: sum of 3 quarters · filed 2021-03-01 | $380.83M 10-K · filed 2022-03-01 |
| 2019-09-30 | $99.04M 10-K · filed 2021-03-01 | $193.71M derived: sum of 2 quarters · filed 2021-03-01 | $280.72M 10-Q · filed 2020-11-05 | $365.13M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $94.67M 10-K · filed 2021-03-01 | $181.68M 10-Q · filed 2020-08-05 | $266.09M derived: sum of 3 quarters · filed 2021-03-01 | $344.58M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $87.01M 10-K · filed 2021-03-01 | $171.43M derived: sum of 2 quarters · filed 2021-03-01 | $249.91M derived: sum of 3 quarters · filed 2021-03-01 | $323.44M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $84.42M 10-K · filed 2020-02-26 | $162.90M derived: sum of 2 quarters · filed 2020-02-26 | $236.43M derived: sum of 3 quarters · filed 2020-02-26 | $301.03M 10-K · filed 2021-03-01 |
| 2018-09-30 | $78.49M 10-K · filed 2020-02-26 | $152.01M derived: sum of 2 quarters · filed 2020-02-26 | $216.62M 10-Q · filed 2019-11-07 | $273.90M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $73.53M 10-K · filed 2020-02-26 | $138.13M 10-Q · filed 2019-08-07 | $195.41M derived: sum of 3 quarters · filed 2020-02-26 | $241.36M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $64.60M 10-K · filed 2020-02-26 | $121.88M derived: sum of 2 quarters · filed 2020-02-26 | $167.84M derived: sum of 3 quarters · filed 2020-02-26 | $202.85M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $57.28M 10-K · filed 2019-02-28 | $103.23M derived: sum of 2 quarters · filed 2019-02-28 | $138.24M derived: sum of 3 quarters · filed 2019-02-28 | $154.58M 10-K · filed 2020-02-26 |
| 2017-09-30 | $45.95M 10-K · filed 2019-02-28 | $80.97M derived: sum of 2 quarters · filed 2019-02-28 | $97.31M 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $35.01M 10-K · filed 2019-02-28 | $51.35M derived: sum of 2 quarters · filed 2019-02-28 | ||
| 2017-03-31 | $16.34M 10-K · filed 2019-02-28 | |||
| 2016-12-31 | $5.42M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |